ESPERION THERAPEUTICS INC (ESPR) Forecast, Price Target & Analyst Ratings

NASDAQ:ESPR • US29664W1053

Current stock price

2.62 USD
+0.07 (+2.75%)
At close:
2.6206 USD
+0 (+0.02%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ESPERION THERAPEUTICS INC (ESPR).

Forecast Snapshot

Consensus Price Target

Price Target
$6.96
+ 165.73% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
May 4, 2026
Period
Q1 / 2026
EPS Estimate
-$0.02
Revenue Estimate
96.129M
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
78.57%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$6.96
Upside
+ 165.73%
From current price of $2.62 to mean target of $6.96, Based on 14 analyst forecasts
Low
$1.80
Median
$5.10
High
$16.80

Price Target Revisions

1 Month
5.58%
3 Months
5.58%

Price Target Summary

14 Wall Street analysts provided a forecast for the next 12 months for ESPR. The average price target is 6.96 USD. This implies a price increase of 165.73% is expected in the next year compared to the current price of 2.62.
The average price target has been revised upward by 5.58% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

ESPR Current Analyst RatingESPR Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 2 4 6

Analyst Ratings History

ESPR Historical Analyst RatingsESPR Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 5 10

Analyst Ratings Consensus

ChartMill Buy Consensus
78.57%
ESPR was analyzed by 14 analysts. The buy percentage consensus is at 79. So analysts seem to be have mildly positive about ESPR.
In the previous month the buy percentage consensus was at a similar level.
ESPR was analyzed by 14 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-03-13CitizensMaintains Market Outperform -> Market Outperform
2026-03-03NeedhamMaintains Buy -> Buy
2025-11-25Piper SandlerInitiate Overweight
2025-09-19HC Wainwright & Co.Reiterate Buy -> Buy
2025-06-17HC Wainwright & Co.Reiterate Buy -> Buy
2025-05-07NeedhamMaintains Buy -> Buy
2025-04-25NeedhamReiterate Buy -> Buy
2025-04-25HC Wainwright & Co.Reiterate Buy -> Buy
2025-04-17Goldman SachsMaintains Neutral -> Neutral
2025-04-08NeedhamReiterate Buy -> Buy
2025-03-20HC Wainwright & Co.Reiterate Buy -> Buy
2025-03-05Citizens Capital MarketsReiterate Market Outperform -> Market Outperform
2025-03-04HC Wainwright & Co.Reiterate Buy -> Buy
2025-02-11JMP SecuritiesReiterate Market Outperform -> Market Outperform
2025-02-11HC Wainwright & Co.Reiterate Buy -> Buy
2025-01-23JMP SecuritiesReiterate Market Outperform -> Market Outperform
2025-01-23HC Wainwright & Co.Reiterate Buy -> Buy
2025-01-22HC Wainwright & Co.Reiterate Buy -> Buy
2025-01-10HC Wainwright & Co.Reiterate Buy -> Buy
2024-12-18Goldman SachsReiterate Neutral
2024-12-17Cantor FitzgeraldInitiate Overweight
2024-12-13NeedhamReiterate Buy -> Buy
2024-12-13HC Wainwright & Co.Reiterate Buy -> Buy
2024-12-12HC Wainwright & Co.Reiterate Buy -> Buy
2024-12-03HC Wainwright & Co.Maintains Buy -> Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date
May 4, 2026
Period
Q1 / 2026
EPS Estimate
-$0.02
Revenue Estimate
96.129M
Revenue Q2Q
47.90%
EPS Q2Q
92.44%
Number of Analysts
9

Next Earnings Revisions

Revenue (1 Month)
-13.96%
Revenue (3 Months)
-13.92%
EPS (1 Month)
-592.00%
EPS (3 Months)
-227.79%

Next Earnings Summary

ESPR is expected to report earnings on 5/4/2026. The consensus EPS estimate for the next earnings is -0.02 USD and the consensus revenue estimate is 96.13M USD.
The next earnings revenue estimate has been revised downward by 13.92% in the past 3 months. Downward revisions are a negative sign and indicate that analysts are more pessimistic about the next earnings compared to 3 months ago.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2033

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
ESPR revenue by date.ESPR revenue by date.
116.334M
54.08%		332.314M
185.66%		403.135M
21.31%		414.91M
2.92%		402.6M
-2.97%		564.29M
40.16%		961.91M
70.46%		1.223B
27.14%		740.06M
-39.49%		664.48M
-10.21%		620.01M
-6.69%
EBITDA
YoY % growth
ESPR ebitda by date.ESPR ebitda by date.
-155.399M
13.18%		54.465M
135.05%		60.378M
10.86%		157.83M
161.40%		61.684M
-60.92%		215.83M
249.90%		218.48M
1.23%		274.89M
25.82%		318.75M
15.96%		352.92M
10.72%		379.13M
7.43%
EBIT
YoY % growth
ESPR ebit by date.ESPR ebit by date.
-155.563M
13.34%		54.402M
134.97%		60.273M
10.79%		100.24M
66.31%		71.649M
-28.52%		138.07M
92.70%		413.56M
199.53%		614.4M
48.56%		376.28M
-38.76%		346.29M
-7.97%		310.9M
-10.22%
Operating Margin
ESPR operating margin by date.ESPR operating margin by date.
-133.72%16.37%14.95%24.16%17.80%24.47%42.99%50.24%50.84%52.11%50.14%
EPS
YoY % growth
ESPR eps by date.ESPR eps by date.
-2.12
40.28%		-0.25
88.21%		-0.17
32.00%		0.14
183.93%		0.22
55.99%		0.90
303.30%		1.57
75.00%		2.14
36.04%		1.50
-29.83%		1.17
-21.77%		0.85
-27.83%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26
EPS
Q2Q % growth		-0.02
92.44%		0.01
133.15%		0.01
109.08%		0.04
-81.77%
Revenue
Q2Q % growth		96.129M
47.90%		101.62M
23.35%		105.72M
21.09%		106.76M
-36.62%
EBITDA
Q2Q % growth		38.786M
275.74%		31.79M
344.74%		29.96M
403.24%		N/A
EBIT
Q2Q % growth		26.276M
218.92%		21.002M
196.01%		22.508M
326.01%		24.174M
-71.64%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

ESPR Yearly Revenue VS EstimatesESPR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
ESPR Yearly EPS VS EstimatesESPR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 -2 -4 -6 -8 -10

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
93.81%
EPS Next 5 Year
70.88%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
10.55%
Revenue Next 5 Year
23.97%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
40.18%
EBIT Next 5 Year
28.54%
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

ESPERION THERAPEUTICS INC / ESPR Forecast FAQ

What is the average price target for ESPERION THERAPEUTICS INC (ESPR) stock?

14 analysts have analysed ESPR and the average price target is 6.96 USD. This implies a price increase of 165.73% is expected in the next year compared to the current price of 2.62.

What is the next earnings date for ESPR stock?

ESPERION THERAPEUTICS INC (ESPR) will report earnings on 2026-05-04.

Can you provide the consensus estimates for ESPERION THERAPEUTICS INC next earnings?

The consensus EPS estimate for the next earnings of ESPERION THERAPEUTICS INC (ESPR) is -0.02 USD and the consensus revenue estimate is 96.13M USD.

What is the expected long term growth rate for ESPR stock?

The expected long term growth rate for ESPERION THERAPEUTICS INC (ESPR) is 10.55%.